Scarica l'app Stockscreener
28.09
14.20%
-4.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HIMS Giù?
Forum
Previsione
Precedente Chiudi:
$32.74
Aprire:
$33.445
Volume 24 ore:
28.34M
Relative Volume:
1.38
Capitalizzazione di mercato:
$6.50B
Reddito:
$2.35B
Utile/perdita netta:
$128.37M
Rapporto P/E:
53.80
EPS:
0.5221
Flusso di cassa netto:
$57.42M
1 W Prestazione:
-14.46%
1M Prestazione:
-14.10%
6M Prestazione:
-5.17%
1 anno Prestazione:
-50.99%
Intervallo 1D:
$27.93
$34.57
Intervallo di 1 settimana:
$27.93
$35.85
Portata 52W:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Nome
Hims Hers Health Inc
Settore
Telefono
415-851-0195
Indirizzo
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
28.09 | 6.50B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.24 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.78 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.81 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.35 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
528.47 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Iniziato | JP Morgan | Overweight |
| 2026-03-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Aggiornamento | Citigroup | Sell → Neutral |
| 2026-03-09 | Aggiornamento | Needham | Hold → Buy |
| 2026-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| 2026-01-12 | Iniziato | Evercore ISI | In-line |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-21 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Downgrade | Needham | Buy → Hold |
| 2025-06-04 | Reiterato | Needham | Buy |
| 2025-04-29 | Downgrade | TD Cowen | Buy → Hold |
| 2025-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Downgrade | Citigroup | Neutral → Sell |
| 2025-01-07 | Iniziato | BTIG Research | Buy |
| 2024-12-17 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-08-22 | Iniziato | Needham | Buy |
| 2024-08-09 | Downgrade | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-04-16 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-10 | Iniziato | Canaccord Genuity | Buy |
| 2024-02-28 | Aggiornamento | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2023-12-07 | Iniziato | Imperial Capital | In-line |
| 2023-07-28 | Iniziato | TD Cowen | Outperform |
| 2023-04-11 | Iniziato | Robert W. Baird | Neutral |
| 2023-02-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-08 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-07-15 | Iniziato | SVB Leerink | Underperform |
| 2022-04-14 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | Deutsche Bank | Hold |
| 2021-12-02 | Iniziato | Jefferies | Hold |
| 2021-11-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Iniziato | BofA Securities | Neutral |
| 2021-05-20 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Iniziato | Truist | Hold |
| 2021-03-09 | Iniziato | Credit Suisse | Neutral |
| 2021-03-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Iniziato | Citigroup | Neutral |
| 2021-02-12 | Iniziato | Piper Sandler | Neutral |
| 2021-02-08 | Iniziato | Tigress Financial | Buy |
Mostra tutto
Hims Hers Health Inc Borsa (HIMS) Ultime notizie
Hims & Hers Health Stock (HIMS) Opinions on FDA Peptide Decisions - Quiver Quantitative
Why Is HIMS Stock Rallying 13% Today? - Stocktwits
A Hims cofounder fired his entire marketing team for AI. Now his 24/7 online vet service is growing 20% a month - Yahoo Finance
FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight - Yahoo Finance
Hims & Hers Health (HIMS) Shares Fall After FDA Panel's Negative Vote on Emideltide - GuruFocus
HIMS Maintains by Truist Securities -- Price Target Raised to $2 - GuruFocus
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know - Yahoo Finance
HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder - Barchart.com
Hims & Hers (HIMS) Stock Looks Cheap On Cash Flow But Pricey After A 313% Run - Yahoo Finance
HIMS Stock Dives Sharply as Uninsured Patients Raise Concerns while FDA Process Remains Uncertain - FXLeaders
HIMS Stock Falls Over 10% Amid Market Fluctuations - GuruFocus
Hims & Hers down as FDA advisors snub first peptide (HIMS:NYSE) - Seeking Alpha
Is Today’s Dip a Buying Opportunity for Hims & Hers Health (HIMS) Stock? - TipRanks
Hims & Hers Health Slides as Traders Fade Peptide Rally - Quiver Quantitative
Hims & Hers: Peptide Ruling A Positive, Operational Good Sense Makes 'Buy' Case (Upgrade) - Seeking Alpha
HIMS Stock Climbs Overnight As FDA Advisory Panel Backs 4 Peptides — ‘Pharma Bro’ Martin Shkreli Goes Short - Stocktwits
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now? - Yahoo Finance
Peptide catalyst lift for Hims & Hers (NYSE:HIMS) limited by FDA review timetable - TechStock²
Hims & Hers Health: Favorable Decision on Peptides Lifts Investor Appetite but Uncertainty Very High - Morningstar
Telehealth firms urge FDA to legalize peptides, with guardrails - Crain's New York
What Shapes Hims & Hers Health (NYSE:HIMS) Russell 2000 View? - Kalkine Media
FDA Peptide Shift And Leadership Change Could Be A Game Changer For Hims & Hers Health (HIMS) - simplywall.st
Is It Too Late to Buy Hims & Hers Health Inc (HIMS) After 3.4% R - GuruFocus
Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $30.38, Implies 4% Downside - TradingView
Hims & Hers Health (HIMS) Gains On FDA Panel News, Is The Valuation Gap Still Wide? - Yahoo Finance
HIMS Maintained by Citigroup -- Price Target Raised to $35.00 - GuruFocus
Hims & Hers Stock: What FDA Peptide Decision Means for Telehealth Strategy - Barron's
Hims & Hers Stock Jumps 13% After FDA Panel Backs BPC-157 for Compounding - finance.biggo.com
Hims & Hers Health, Inc. stock Analysis: FDA Catalyst Impacts Neutral Regime - The Cryptonomist
FDA advisers back first of seven peptides under review for looser rules - Reuters
Hims & Hers Health (NYSE:HIMS) rises as FDA BPC-157 decision turns market attention to revenue per subscriber - TechStock²
HIMS Shares Surge Over 10% Following FDA Panel Decision - GuruFocus
HIMS Stock Surges Following FDA Advisory Panel Decision - GuruFocus
Hims & Hers gains as FDA panel endorses peptide BPC-157 (HIMS) - Seeking Alpha
Hims & Hers Health shares jump on FDA’s push to expand BPC-157 access - Investing.com Canada
Hims & Hers stock jumps after FDA panel backs BPC-157 access - Investing.com Canada
Hims & Hers stands to gain if the FDA loosens restrictions on peptides - Reuters
Telehealth Firms Urge FDA to Legalize Peptides, With Guardrails - Bloomberg.com
$Hims & Hers Health (HIMS.US)$ - Moomoo
Hims & Hers Health Inc (HIMS) Shares Fall 3.2% -- What GF Score of 83 Tells Investors - GuruFocus
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
HIMS Stock Slips Overnight: Hims & Hers Bulks Up Debt Raise To $350M For Eucalyptus Buyout, AI Push - Stocktwits
The FDA Is About to Weigh in on the Great Peptide Debate - inc.com
Form 144 Hims & Hers Health For: 22 July By Investing.com - Investing.com Canada
Hims & Hers Health, Inc. SEC Filing (Jul 22, 2026) - Stock Titan
HIMS Sees Surge in App Downloads Amid Peptide Opportunity - GuruFocus
$Hims & Hers Health (HIMS.US)$ 24th July is the key peptide hearing? - Moomoo
HIMS Stock Snaps 3-Day Losing Streak: FDA Adds 8 New Peptide Voters Deemed ‘More Qualified And Less Conflicted’ - Stocktwits
Lobbying Update: $290,000 of HIMS & HERS HEALTH INC. lobbying was just disclosed - Quiver Quantitative
Hims & Hers stock analysis: growth story meets credibility crisis ahead of FDA catalyst - Investing.com Canada
Hims & Hers Health Stock Short Interest Falls to 31.82% - Quiver Quantitative
Hims Hers Health Inc Azioni (HIMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Hims Hers Health Inc Azioni (HIMS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | Chief Financial Officer |
Jul 17 '26 |
Option Exercise |
5.01 |
7,163 |
35,887 |
291,484 |
| Okupe Oluyemi | Chief Financial Officer |
Jul 17 '26 |
Sale |
31.99 |
7,163 |
229,168 |
284,321 |
| Okupe Oluyemi | Chief Financial Officer |
Jul 06 '26 |
Option Exercise |
5.01 |
7,163 |
35,887 |
291,484 |
| Okupe Oluyemi | Chief Financial Officer |
Jul 06 '26 |
Sale |
36.49 |
7,163 |
261,351 |
284,321 |
0.15%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):